{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,1,13]],"date-time":"2026-01-13T00:48:21Z","timestamp":1768265301187,"version":"3.49.0"},"reference-count":35,"publisher":"Springer Science and Business Media LLC","issue":"6","license":[{"start":{"date-parts":[[2016,11,23]],"date-time":"2016-11-23T00:00:00Z","timestamp":1479859200000},"content-version":"unspecified","delay-in-days":0,"URL":"http:\/\/www.springer.com\/tdm"}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["Am J Cardiovasc Drugs"],"published-print":{"date-parts":[[2016,12]]},"DOI":"10.1007\/s40256-016-0203-2","type":"journal-article","created":{"date-parts":[[2016,11,23]],"date-time":"2016-11-23T03:40:51Z","timestamp":1479872451000},"page":"461-468","update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":31,"title":["Sebelipase Alfa: A Review in Lysosomal Acid Lipase Deficiency"],"prefix":"10.1007","volume":"16","author":[{"given":"James E.","family":"Frampton","sequence":"first","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"297","published-online":{"date-parts":[[2016,11,23]]},"reference":[{"issue":"6","key":"203_CR1","doi-asserted-by":"crossref","first-page":"1230","DOI":"10.1016\/j.jhep.2013.02.014","volume":"58","author":"DL Bernstein","year":"2013","unstructured":"Bernstein DL, H\u00fclkova H, Bialer MG, et al. Cholesteryl ester storage disease: review of the findings in 135 reported patients with an underdiagnosed disease. J Hepatol. 2013;58(6):1230\u201343.","journal-title":"J Hepatol."},{"issue":"1","key":"203_CR2","doi-asserted-by":"crossref","first-page":"21","DOI":"10.1016\/j.atherosclerosis.2014.04.003","volume":"235","author":"Z Reiner","year":"2014","unstructured":"Reiner Z, Guardamagna O, Nair D, et al. Lysosomal acid lipase deficiency\u2014an under-recognized cause of dyslipidaemia and liver dysfunction. Atherosclerosis. 2014;235(1):21\u201330.","journal-title":"Atherosclerosis."},{"issue":"Suppl 1","key":"203_CR3","first-page":"125","volume":"12","author":"AF Porto","year":"2014","unstructured":"Porto AF. Lysosomal acid lipase deficiency: diagnosis and treatment of wolman and cholesteryl ester storage diseases. Pediatr Endocrinol Rev. 2014;12(Suppl 1):125\u201332.","journal-title":"Pediatr Endocrinol Rev."},{"issue":"3","key":"203_CR4","first-page":"129","volume":"73","author":"B Sjouke","year":"2015","unstructured":"Sjouke B, van der Stappen JWJ, Groener JEM, et al. Hypercholesterolaemia and hepatosplenomegaly: two manifestations of cholesteryl ester storage disease. Neth J Med. 2015;73(3):129\u201332.","journal-title":"Neth J Med."},{"issue":"16","key":"203_CR5","doi-asserted-by":"crossref","first-page":"1935","DOI":"10.1007\/s40265-015-0479-6","volume":"75","author":"M Shirley","year":"2015","unstructured":"Shirley M. Sebelipase alfa: first global approval. Drugs. 2015;75(16):1935\u201340.","journal-title":"Drugs."},{"issue":"3","key":"203_CR6","doi-asserted-by":"crossref","first-page":"950","DOI":"10.1002\/hep.26289","volume":"58","author":"M Balwani","year":"2013","unstructured":"Balwani M, Breen C, Enns GM, et al. Clinical effect and safety profile of recombinant human lysosomal acid lipase in patients with cholesteryl ester storage disease. Hepatology. 2013;58(3):950\u20137.","journal-title":"Hepatology."},{"key":"203_CR7","unstructured":"European Medicines Agency. Kanuma (sebelipase alfa): summary of product characteristics. 2015. http:\/\/www.ema.europa.eu . Accessed 18 July 2015."},{"key":"203_CR8","unstructured":"Alexion Pharmaceuticals Inc. Kanuma (sebelipase alfa) injection, for intravenous use: US prescribing information. 2015. http:\/\/www.accessdata.fda.gov . Accessed 18 July 2016."},{"key":"203_CR9","unstructured":"Alexion Pharmaceuticals, Inc. Kanuma\u00ae (sebelipase alfa) receives marketing approval in Japan for treatment of patients with lysosomal acid lipase deficiency (LAL-D) [media release]. http:\/\/news.alexionpharma.com . 28 Mar 2016."},{"key":"203_CR10","unstructured":"European Medicines Agency. Committee for Medicinal Products for Human Use (CHMP) assessment report. Kanuma. International non-proprietary name: sebelipase alfa. Procedure No. EMEA\/H\/C\/004004\/0000. 2015. http:\/\/www.ema.europa.eu Accessed 18 July 2016."},{"key":"203_CR11","doi-asserted-by":"crossref","unstructured":"Quinn AG, Harvey A, Chen M, et al. SBC-102, a recombinant enzyme replacement therapy, corrects key abnormalities due to lysosomal acid lipase deficiency [abstract]. In: American Society of Human Genetics Annual Meeting, 2010.","DOI":"10.1016\/j.ymgme.2010.11.125"},{"issue":"Suppl 1","key":"203_CR12","doi-asserted-by":"crossref","first-page":"S358","DOI":"10.1016\/S0168-8278(11)60902-1","volume":"54","author":"M Leavitt","year":"2011","unstructured":"Leavitt M, Burt AD, Hu W, et al. Recombinant lysosomal acid lipase normalizes liver weight, transaminases and histopathological abnormalities in an in vivo model of cholesteryl ester storage disease [abstract no. 900]. J Hepatol. 2011;54(Suppl 1):S358.","journal-title":"J Hepatol."},{"issue":"Suppl 1","key":"203_CR13","first-page":"E20","volume":"52","author":"M Leavitt","year":"2011","unstructured":"Leavitt M, Hu W, Canty D, et al. Efficacy of SBC-102, a recombinant enzyme replacement therapy, across a broad range of doses in an in vivo model of lysosomal acid lipase deficiency [abstract no. PA-H-0036]. J Pediatr Gastroenterol Nutr. 2011;52(Suppl 1):E20.","journal-title":"J Pediatr Gastroenterol Nutr."},{"issue":"3","key":"203_CR14","doi-asserted-by":"crossref","first-page":"543","DOI":"10.1016\/j.jhep.2013.04.016","volume":"59","author":"PE Thelwall","year":"2013","unstructured":"Thelwall PE, Smith FE, Leavitt MC, et al. Hepatic cholesteryl ester accumulation in lysosomal acid lipase deficiency: non-invasive identification and treatment monitoring by magnetic resonance. J Hepatol. 2013;59(3):543\u20139.","journal-title":"J Hepatol."},{"issue":"S1","key":"203_CR15","first-page":"830A","volume":"56","author":"J Rutkowski","year":"2012","unstructured":"Rutkowski J, Burt AD, Leavitt M, et al. Recombinant human lysosomal acid lipase decreases hepatic macrophage aggregates and colocalized fibrosis in a rat model of lysosomal acid lipase deficiency [abstract no. 1351]. Hepatology. 2012;56(S1):830A.","journal-title":"Hepatology."},{"issue":"2","key":"203_CR16","doi-asserted-by":"crossref","first-page":"S80","DOI":"10.1016\/j.ymgme.2012.11.214","volume":"108","author":"JV Rutkowski","year":"2013","unstructured":"Rutkowski JV, Burt AD, Leavitt MC, et al. Co-localization of macrophage aggregation and fibrosis in a rat model of lysosomal acid lipase (LAL) deficiency and the effects of enzyme replacement with SBC-102 [abstract]. Mol Genet Metab. 2013;108(2):S80\u20131.","journal-title":"Mol Genet Metab."},{"key":"203_CR17","unstructured":"US National Institutes of Health. ClinicalTrials.gov identifier NCT01371825. 2016. https:\/\/clinicaltrials.gov . Accessed 23 June 2016."},{"issue":"2","key":"203_CR18","first-page":"S59","volume":"114","author":"SA Jones","year":"2015","unstructured":"Jones SA, Plantaz D, Vara R, et al. Effect of sebelipase alfa on survival and liver function in infants with rapidly progressive lysosomal acid lipase deficiency [abstract no. 120]. Mol Genet Metab. 2015;114(2):S59.","journal-title":"Mol Genet Metab."},{"issue":"Suppl 2","key":"203_CR19","doi-asserted-by":"crossref","first-page":"S811","DOI":"10.1016\/S0168-8278(15)31408-2","volume":"62","author":"S Jones","year":"2015","unstructured":"Jones S, Plantaz D, Vara R, et al. Impact of sebelipase alfa on survival and liver function in infants with rapidly progressive lysosomal acid lipase deficiency [abstract no. P1212]. J Hepatol. 2015;62(Suppl 2):S811.","journal-title":"J Hepatol."},{"issue":"2","key":"203_CR20","doi-asserted-by":"crossref","first-page":"S63","DOI":"10.1016\/j.ymgme.2015.12.308","volume":"117","author":"SA Jones","year":"2016","unstructured":"Jones SA, Brassier A, Hughes J, et al. Effect of sebelipase alfa on survival and liver function in infants with rapidly progressive lysosomal acid lipase deficiency: 2-year follow-up data [abstract no. 150]. Mol Genet Metab. 2016;117(2):S63.","journal-title":"Mol Genet Metab."},{"issue":"5","key":"203_CR21","first-page":"452","volume":"18","author":"S Jones","year":"2016","unstructured":"Jones S, Valayannopoulos V, Schneider E, et al. Rapid progression and mortality of lysosomal acid lipase deficiency presenting in infants. 2016;18(5):452\u20138.","journal-title":"Rapid progression and mortality of lysosomal acid lipase deficiency presenting in infants."},{"issue":"11","key":"203_CR22","doi-asserted-by":"crossref","first-page":"1010","DOI":"10.1056\/NEJMoa1501365","volume":"373","author":"BK Burton","year":"2015","unstructured":"Burton BK, Balwani M, Feillet F, et al. A phase 3 trial of sebelipase alfa in lysosomal acid lipase deficiency. N Engl J Med. 2015;373(11):1010\u201320.","journal-title":"N Engl J Med."},{"issue":"3","key":"203_CR23","doi-asserted-by":"crossref","first-page":"678","DOI":"10.1016\/j.jacl.2016.03.046","volume":"10","author":"DP Wilson","year":"2016","unstructured":"Wilson DP, Marulkar S, Tripuraneni R, et al. Sebelipase alfa improves atherogenic biomarkers in adults and children with lysosomal acid lipase deficiency [abstract no. 133]. J Clin Lipidol. 2016;10(3):678\u20139.","journal-title":"J Clin Lipidol."},{"key":"203_CR24","unstructured":"Furuya KN, Marulkar S, Friedman M, et al. Long-term benefit of sebelipase alfa over 52\u00a0weeks in children and adults with lysosomal acid lipase deficiency (ARISE trial) [abstract no. 164]. J Pediatr Gastroenterol Nutr. 2016;63:164(Suppl 2):s50."},{"issue":"Suppl 1","key":"203_CR25","first-page":"281A","volume":"64","author":"KN Furuya","year":"2016","unstructured":"Furuya KN, Marulkar S, Friedman M, et al. Long-term benefit of sebelipase alfa over 76\u00a0weeks in children and adults with lysosomal acid lipase deficiency (ARISE trial) [abstract no. 564]. Hepatology. 2016;64(Suppl 1):281A.","journal-title":"Hepatology."},{"key":"203_CR26","unstructured":"Goodman ZD, Burton B, Alaparthi L, et al. Change in liver fibrosis in children and adults with lysosomal acid lipase deficiency after 52\u00a0weeks of sebelipase alfa (ARISE trial) [abstract no. 561]. Hepatology. 2016;64(Suppl 1):279\u201380A. 2016."},{"issue":"5","key":"203_CR27","doi-asserted-by":"crossref","first-page":"1135","DOI":"10.1016\/j.jhep.2014.06.022","volume":"61","author":"V Valayannopoulos","year":"2014","unstructured":"Valayannopoulos V, Malinova V, Honz\u00edk T, et al. Sebelipase alfa over 52\u00a0weeks reduces serum transaminases, liver volume and improves serum lipids in patients with lysosomal acid lipase deficiency. J Hepatol. 2014;61(5):1135\u201342.","journal-title":"J Hepatol."},{"issue":"2","key":"203_CR28","doi-asserted-by":"crossref","first-page":"S113","DOI":"10.1016\/j.ymgme.2013.12.283","volume":"111","author":"CB Whitley","year":"2014","unstructured":"Whitley CB, Valayannopoulos V, Malinova V, et al. Long-term clinical effect and safety of sebelipase alfa in adults with lysosomal acid lipase deficiency [abstract]. Mol Genet Metab. 2014;111(2):S113\u20134.","journal-title":"Mol Genet Metab."},{"key":"203_CR29","doi-asserted-by":"crossref","unstructured":"Valayannopoulos V, Malinova VERA, Sharma R, et al. Effect of sebelipase alfa after 90\u00a0weeks in adults with lysosomal acid lipase deficiency [abstract]. In: 82nd European Atherosclerosis Society Congress, 2014.","DOI":"10.1016\/j.atherosclerosis.2014.05.023"},{"issue":"Suppl 1","key":"203_CR30","first-page":"S160","volume":"37","author":"F Abel","year":"2014","unstructured":"Abel F, Whitley CB, Valayannopoulos V, et al. Effect of sebelipase alfa after 2\u00a0years in adults with lysosomal acid lipase deficiency [abstract no. P-445]. J Inherit Metab Dis. 2014;37(Suppl 1):S160.","journal-title":"J Inherit Metab Dis."},{"issue":"2","key":"203_CR31","doi-asserted-by":"crossref","first-page":"S47","DOI":"10.1016\/j.ymgme.2015.12.260","volume":"117","author":"M Friedman","year":"2016","unstructured":"Friedman M, Valayannopoulos V, Grande CC, et al. Safety findings from 3 trials of treatment with sebelipase alfa in children and adults with lysosomal acid lipase deficiency [abstract no. 102]. Mol Genet Metab. 2016;117(2):S47.","journal-title":"Mol Genet Metab."},{"issue":"5","key":"203_CR32","doi-asserted-by":"crossref","first-page":"287","DOI":"10.1358\/dot.2016.52.5.2488974","volume":"52","author":"DM Paton","year":"2016","unstructured":"Paton DM. Sebelipase alfa: enzymatic replacement treatment for lysosomal acid lipase deficiency. Drugs Today. 2016;52(5):287\u201393.","journal-title":"Drugs Today."},{"key":"203_CR33","unstructured":"US National Institutes of Health. ClinicalTrials.gov identifier NCT02193867. 2016. https:\/\/clinicaltrials.gov . Accessed 15 July 2016."},{"key":"203_CR34","unstructured":"US National Institutes of Health. ClinicalTrials.gov identifier NCT02112994. 2016. https:\/\/clinicaltrials.gov . Accessed 15 July 2016."},{"key":"203_CR35","doi-asserted-by":"crossref","first-page":"92","DOI":"10.1186\/s13023-015-0305-y","volume":"10","author":"Y Schuller","year":"2015","unstructured":"Schuller Y, Hollak CEM, Biegstraaten M. The quality of economic evaluations of ultra-orphan drugs in Europe\u2014a systematic review. Orphanet J Rare Dis. 2015;10:92.","journal-title":"Orphanet J Rare Dis."}],"container-title":["American Journal of Cardiovascular Drugs"],"original-title":[],"language":"en","link":[{"URL":"http:\/\/link.springer.com\/content\/pdf\/10.1007\/s40256-016-0203-2.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"http:\/\/link.springer.com\/article\/10.1007\/s40256-016-0203-2\/fulltext.html","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"http:\/\/link.springer.com\/content\/pdf\/10.1007\/s40256-016-0203-2.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2019,9,15]],"date-time":"2019-09-15T18:00:24Z","timestamp":1568570424000},"score":1,"resource":{"primary":{"URL":"http:\/\/link.springer.com\/10.1007\/s40256-016-0203-2"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2016,11,23]]},"references-count":35,"journal-issue":{"issue":"6","published-print":{"date-parts":[[2016,12]]}},"alternative-id":["203"],"URL":"https:\/\/doi.org\/10.1007\/s40256-016-0203-2","relation":{},"ISSN":["1175-3277","1179-187X"],"issn-type":[{"value":"1175-3277","type":"print"},{"value":"1179-187X","type":"electronic"}],"subject":[],"published":{"date-parts":[[2016,11,23]]}}}